<table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.01202.003</object-id><label>Table 1.</label><caption><title>Demographic and clinical data among subjects with new-onset rheumatoid arthritis (NORA), chronic, treated rheumatoid arthritis (CRA), psoriatic arthritis (PsA), and healthy controls (HLT)</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.01202.003">http://dx.doi.org/10.7554/eLife.01202.003</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>NORA</th><th>CRA</th><th>PsA</th><th>Healthy</th></tr><tr><th/><th>(n = 44)</th><th>(n = 26)</th><th>(n = 16)</th><th>(n = 28)</th></tr></thead><tbody><tr><td>Age, years, mean (median)</td><td>42.4 (40.0)</td><td>50.0 (49.0)</td><td>46.3 (46.0)</td><td>42.8 (40.0)</td></tr><tr><td>Female, %</td><td align="char" char=".">75</td><td align="char" char=".">88</td><td align="char" char=".">56</td><td align="char" char=".">75</td></tr><tr><td>Disease duration, months, mean (median)</td><td>5.4 (2.0)</td><td>72.3 (48.0)</td><td>0.8 (0.0)</td><td>N/A</td></tr><tr><td colspan="5">Disease activity parameters</td></tr><tr><td>&#8195;ESR, mm/h, mean</td><td align="char" char=".">34.6</td><td align="char" char=".">33.5</td><td align="char" char=".">19.7</td><td align="char" char=".">10.2</td></tr><tr><td>&#8195;CRP, mg/l, mean</td><td align="char" char=".">20.6</td><td align="char" char=".">8.2</td><td align="char" char=".">7.6</td><td align="char" char=".">1.1</td></tr><tr><td>&#8195;DAS28, mean (median)</td><td>5.4 (5.7)</td><td>4.7 (5.0)</td><td>4.8 (4.7)</td><td>N/A</td></tr><tr><td>&#8195;Patient VAS pain, mm, mean (median)</td><td>61.4 (57.5)</td><td>51.5 (62.5)</td><td>50.6 (45.0)</td><td>N/A</td></tr><tr><td>&#8195;TJC-28, mean (median)</td><td>11.2 (8.5)</td><td>7.6 (7.0)</td><td>8.8 (6.5)</td><td>N/A</td></tr><tr><td>&#8195;SJC-28, mean (median)</td><td>8.3 (8.0)</td><td>4.6 (3.0)</td><td>4.8 (3.0)</td><td>N/A</td></tr><tr><td colspan="5">Autoantibody status</td></tr><tr><td>&#8195;IgM-RF positive, %</td><td align="char" char=".">95</td><td align="char" char=".">81</td><td align="char" char=".">13</td><td align="char" char=".">11</td></tr><tr><td>&#8195;ACPA positive, %</td><td align="char" char=".">100</td><td align="char" char=".">85</td><td align="char" char=".">6</td><td align="char" char=".">7</td></tr><tr><td>&#8195;IgM-RF and/or ACPA positive, %</td><td align="char" char=".">100</td><td align="char" char=".">96</td><td align="char" char=".">13</td><td align="char" char=".">14</td></tr><tr><td>&#8195;IgM-RF titer, kU/l, mean (median)</td><td>341.3(157.0)</td><td>178.2 (89.0)</td><td>3.6 (0.0)</td><td>20.5 (0.0)</td></tr><tr><td>&#8195;ACPA titer, kAU/l, mean (median)</td><td>117.6 (114.0)</td><td>90.8 (57.0)</td><td>1.6 (0.0)</td><td>9.6 (0.0)</td></tr><tr><td colspan="5">Medication use</td></tr><tr><td>&#8195;Methotrexate, %</td><td align="char" char=".">0</td><td align="char" char=".">42</td><td align="char" char=".">6</td><td align="char" char=".">0</td></tr><tr><td>&#8195;Prednisone, %</td><td align="char" char=".">0</td><td align="char" char=".">15</td><td align="char" char=".">6</td><td align="char" char=".">0</td></tr><tr><td>&#8195;Biological agent, %</td><td align="char" char=".">0</td><td align="char" char=".">12</td><td align="char" char=".">0</td><td align="char" char=".">0</td></tr></tbody></table></table-wrap>